ClinicalTrials.gg
CompletedNCT00835237Updated Jan 3, 2020Results posted

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

A Phase 3 interventional study of Boostrix® and Decavac™ in Tetanus, Acellular Pertussis and Diphtheria, sponsored by GlaxoSmithKline. Completed at 24 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-03.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,332
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.

Enrollment
5th of 22
1,332 · median 554
Started
2009
the only one that year
Phase 3
12 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
18 of 22
GlaxoSmithKline

Among the 22 studies testing boostrix in Tetanus, this one is the 5th largest by enrollment, is the only one that started in 2009, is one of 12 in phase 3, and was the 10th registered.

Tetanus

318 studies on the registry are indexed under Tetanus; 29 are open to participants now.

Browse Tetanus studies →

Open to participants now

2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About boostrix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing boostrix in Tetanus, or all of them as a file.
02

Study summary

This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.

03

Conditions studied

  • Tetanus
  • Acellular Pertussis
  • Diphtheria
  • Diphtheria-Tetanus-acellular Pertussis Vaccines

Browse trials for

Keywords

  • Boostrix®
  • adults
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that can and will comply with the requirements of the protocol should be enrolled in the study.
  • Males or females 65 years of age and older at the time of study entry.
  • Free of an acute aggravation of the health status as established by medical history and medical history and clinical examination before entering into the study.
  • Written from all subjects.

Exclusion criteria

Exclusion Criteria:

  • Administration of a diphtheria-tetanus (Td) booster within the previous 5 years.
  • Administration of a Tdap vaccine at any time prior to study entry.
  • History of diphtheria and/or tetanus and/or pertussis disease.
  • Use of any or non-registered drug or vaccine other than the study vaccines within 30 days preceding vaccination, or planned use during the entire study period.
  • Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for ) prior to enrolment in this study, with the exception of influenza, vaccine, which may be administered at any time up to or during the study period, including the day of study vaccination.
  • Planned administration of any vaccine not foreseen by the study protocol up to 30 days following vaccination, with the exception of influenza, vaccine, which may be administered at any time up to or during the study period, including the day of study vaccination. Pneumococcal and zoster vaccines can be administered at the discretion of the investigator when the subject comes back at Visit 2.
  • Chronic administration of or other immune-modifying drugs within six months prior to vaccination or planned administration during the study period.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
  • History of serious allergic reaction following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or any component of the study vaccines.
  • History of encephalopathy within seven days of administration of a previous booster dose of pertussis vaccine that is not attributable to another identifiable cause.
  • Progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy: pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized.
  • Acute (active) pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation or pre-existing laboratory screening tests.
  • Acute disease at the time of vaccination.
  • Administration of immunoglobulins and/or any blood products within the three months preceding vaccination, or planned administration during the study period.
  • Any medical condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,332 participants (actual)

Study arms

  • Experimental
    Boostrix Group

    Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)

    Biological: Boostrix®

  • Active comparator
    Decavac Group

    Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)

    Biological: Decavac™

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value

    Antibodies against vaccine antigens assessed were: anti-diphtheria (anti-D) and anti-tetanus (anti-T). Anti-D antibody cut-off value assessed was ≥ 0.1 International Unit per milliliter (IU/mL) Anti-T antibody cut-off values assessed were ≥ 0.1 IU/mL and ≥ 1.0 IU/mL

    Time frame: One month after vaccination.

  2. Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration

    Concentration for anti-PT, anti-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per millilitre (EL.U/mL)

    Time frame: Before (PRE) and one month after vaccination (POST)

Secondary outcomes

  1. Anti-T and Anti-D Antibody Concentrations

    Concentrations for anti-T and anti-D antibodies given as GMC in IU/mL.

    Time frame: Before (PRE) and one month after vaccination (POST)

  2. Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off

    Booster response defined as : For initially seronegative subjects (\< 0.1 IU/mL), antibody concentration ≥ 0.4 IU/mL one month after vaccination. For initially seropositive subjects (≥ 0.1 IU/mL): antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.

    Time frame: One month after vaccination

  3. Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off

    Booster response defined as : For initially seronegative subjects (\< 5 EL.U/mL), antibody concentration ≥ 20 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration \< 20 EL.U/mL: antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration ≥ 20 EL.U/mL : antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.

    Time frame: One month after vaccination

  4. Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.

    Vaccine response using alternative definitions defined as: For initially seronegative subjects (\< 5 EL.U/mL ), antibody concentration ≥ 10 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL), antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.

    Time frame: One month after vaccination

  5. Number of Subjects Reporting Solicited Local Symptoms

    Solicited local symptoms assessed include pain, redness and swelling.

    Time frame: Within the 4-day (Day 0-3) post-vaccination period

  6. Number of Subjects Reporting Solicited General Symptoms

    Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, and fever

    Time frame: Within the 4-day (Day 0-3) post-vaccination period

  7. Number of Subjects Reporting Unsolicited Adverse Events (AE)

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Within the 31-day (Day 0-30) post-vaccination period

  8. Number of Subjects Reporting Serious Adverse Events (SAE)

    An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

    Time frame: From the vaccination up to Day 182

07

Results

Posted Aug 5, 2010

Participant flow

Participant flow — Overall Study
MilestoneBoostrix GroupDecavac Group
Started887445
Completed881445
Not completed60
Withdrew: Lost to follow-up40
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryNumber of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value

Antibodies against vaccine antigens assessed were: anti-diphtheria (anti-D) and anti-tetanus (anti-T). Anti-D antibody cut-off value assessed was ≥ 0.1 International Unit per milliliter (IU/mL) Anti-T antibody cut-off values assessed were ≥ 0.1 IU/mL and ≥ 1.0 IU/mL

Time frame:
One month after vaccination.
Reported as:
Number · subjects
Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value
subjectsBoostrix GroupDecavac Group
Anti-D (≥ 0.1 IU/mL) (N= 859;432)729374
Anti-T (≥ 0.1 IU/mL) (N= 864;439)836428
Anti-T (≥ 1.0 IU/mL) (N= 864;439)767395
PrimaryAnti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration

Concentration for anti-PT, anti-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per millilitre (EL.U/mL)

Time frame:
Before (PRE) and one month after vaccination (POST)
Reported as:
Geometric mean · EL.U/mL
Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration
EL.U/mLBoostrix GroupDecavac Group
Anti-PT (PRE) (N=859;433)6.6 (6.1 to 7.1)6.5 (5.8 to 7.2)
Anti-PT (POST) (N=852;431)49.1 (44.9 to 53.7)6.4 (5.8 to 7.1)
Anti-FHA (PRE) (N=848;430)50.2 (46.2 to 54.5)44.3 (39.5 to 49.5)
Anti-FHA (POST) (N=835;428)689.0 (638.8 to 743.1)44.4 (39.7 to 49.7)
Anti-PRN (PRE) (N=864;439)8.1 (7.4 to 8.8)7.8 (6.9 to 8.8)
Anti-PRN (POST) (N=865;439)104.2 (91.3 to 118.9)7.7 (6.8 to 8.7)
SecondaryAnti-T and Anti-D Antibody Concentrations

Concentrations for anti-T and anti-D antibodies given as GMC in IU/mL.

Time frame:
Before (PRE) and one month after vaccination (POST)
Reported as:
Geometric mean · IU/mL
Anti-T and Anti-D Antibody Concentrations
IU/mLBoostrix GroupDecavac Group
Anti-D (PRE) (N=844;430)0.2 (0.2 to 0.2)0.2 (0.1 to 0.2)
Anti-D (POST) (N=859;432)0.9 (0.8 to 1.0)0.8 (0.7 to 1.0)
Anti-T (PRE) (N=864;439)0.6 (0.6 to 0.7)0.6 (0.5 to 0.7)
Anti-T (POST) (N=864;439)4.0 (3.6 to 4.3)7.1 (6.1 to 8.1)
SecondaryNumber of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off

Booster response defined as : For initially seronegative subjects (\< 0.1 IU/mL), antibody concentration ≥ 0.4 IU/mL one month after vaccination. For initially seropositive subjects (≥ 0.1 IU/mL): antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.

Time frame:
One month after vaccination
Reported as:
Number · subjects
Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off
subjectsBoostrix GroupDecavac Group
Anti-D (N=842;428)383189
Anti-T (N=863;439)438306
SecondaryNumber of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off

Booster response defined as : For initially seronegative subjects (\< 5 EL.U/mL), antibody concentration ≥ 20 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration \< 20 EL.U/mL: antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration. For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration ≥ 20 EL.U/mL : antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.

Time frame:
One month after vaccination
Reported as:
Number · subjects
Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off
subjectsBoostrix GroupDecavac Group
Anti-PT (N=846;430)585430
Anti-FHA (N=821;422)7627
Anti-PRN (N=864;439)6389
SecondaryNumber of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.

Vaccine response using alternative definitions defined as: For initially seronegative subjects (\< 5 EL.U/mL ), antibody concentration ≥ 10 EL.U/mL one month after vaccination. For initially seropositive subjects (≥ 5 EL.U/mL), antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.

Time frame:
One month after vaccination
Reported as:
Number · subjects
Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.
subjectsBoostrix GroupDecavac Group
Anti-PT (N=846;430)6999
Anti-FHA (N=821;422)7658
Anti-PRN (N=864;439)71411
SecondaryNumber of Subjects Reporting Solicited Local Symptoms

Solicited local symptoms assessed include pain, redness and swelling.

Time frame:
Within the 4-day (Day 0-3) post-vaccination period
Reported as:
Number · subjects
Number of Subjects Reporting Solicited Local Symptoms
subjectsBoostrix GroupDecavac Group
Pain190123
Redness9556
Swelling6652
SecondaryNumber of Subjects Reporting Solicited General Symptoms

Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, and fever

Time frame:
Within the 4-day (Day 0-3) post-vaccination period
Reported as:
Number · subjects
Number of Subjects Reporting Solicited General Symptoms
subjectsBoostrix GroupDecavac Group
Fatigue11066
Gastrointestinal symptoms6741
Headache10152
Fever1811
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events (AE)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Within the 31-day (Day 0-30) post-vaccination period
Reported as:
Number · subjects
Number of Subjects Reporting Unsolicited Adverse Events (AE)
subjectsBoostrix GroupDecavac Group
Number of Subjects Reporting Unsolicited Adverse Events (AE)15264
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAE)

An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

Time frame:
From the vaccination up to Day 182
Reported as:
Number · subjects
Number of Subjects Reporting Serious Adverse Events (SAE)
subjectsBoostrix GroupDecavac Group
Number of Subjects Reporting Serious Adverse Events (SAE)3710

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Boostrix Group—37/887 (4.2%)351/887 (39.6%)
Decavac Group—10/445 (2.2%)202/445 (45.4%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventBoostrix GroupDecavac Group
Coronary artery diseaseCardiac disorders3/8870/445
Myocardial infarctionCardiac disorders2/8871/445
Cerebrovascular accidentNervous system disorders2/8870/445
Hip fractureInjury, poisoning and procedural complications2/8870/445
PneumoniaInfections and infestations2/8870/445
Transient ischaemic attackNervous system disorders2/8870/445
ArthralgiaMusculoskeletal and connective tissue disorders0/8871/445
Atrioventricular block completeCardiac disorders0/8871/445
Breast cancer in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/8871/445
DementiaNervous system disorders0/8871/445
Most frequent other events
Most frequent other events
EventBoostrix GroupDecavac Group
PainGeneral disorders190/887123/445
FatigueGeneral disorders110/88766/445
RednessGeneral disorders95/88756/445
SwellingGeneral disorders66/88752/445
HeadacheGeneral disorders101/88752/445
Gastrointestinal symptomsGeneral disorders67/88741/445

Baseline characteristics

Age, Continuous
Age, Continuous(years)Boostrix GroupDecavac GroupTotal
Mean71.6 ± 5.3571.9 ± 5.6271.7 ± 5.44
Sex: Female, Male
Sex: Female, Male(Participants)Boostrix GroupDecavac GroupTotal
Female478237715
Male409208617
08

Study locations

24 sites
  • GSK Investigational Site
    Tucson, Arizona 85741, United States
  • GSK Investigational Site
    Los Angeles, California 90057, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46254, United States
  • GSK Investigational Site
    Pratt, Kansas 67124, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Elkridge, Maryland 21075, United States
  • GSK Investigational Site
    Milford, Massachusetts 01757, United States
  • GSK Investigational Site
    Stevensville, Michigan 49127, United States
  • GSK Investigational Site
    High Point, North Carolina 27262, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Mogadore, Ohio 44260, United States
  • GSK Investigational Site
    Wadsworth, Ohio 44281, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Fort Worth, Texas 76135, United States
  • GSK Investigational Site
    West Jordan, Utah 84088, United States
  • GSK Investigational Site
    Williamsburg, Virginia 23185, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
09

References and documents

Publications

  • Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix((R))): results of two randomized trials. Vaccine. 2012 Feb 21;30(9):1721-8. doi: 10.1016/j.vaccine.2011.12.055. Epub 2011 Dec 31. PubMed 22212127 ↗
  • Weston WM et al. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Boostrix™): results of a randomized clinical trial. Abstract presented at the 45th National Immunization Conference (NIC). Washington, USA, 28-31 March 2011.

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Jul 2009, 5 months.

Results were first posted in Aug 2010, 1 year after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Tetanus, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's 5 months is below that.

Counting every sponsor, half of 56 studies reached it within 12 months; a quarter within 6 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2009
First posted
Feb 3, 2009
StartActual
Feb 17, 2009
Primary completionActual
Jul 23, 2009
CompletionActual
Oct 15, 2009
Results first posted
Aug 5, 2010
Last update
Jan 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00835237
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 3, 2009
Start date
Feb 17, 2009
Primary completion
Jul 23, 2009
Completion
Oct 15, 2009
Results posted
Aug 5, 2010
Last update
Jan 3, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion